That is necessary, due to the fact that the method a protein in the body folds figures out if a pharmaceutical will have the ability to bind to that protein and be efficient. Simply put, we need to understand how these proteins fold if we desire a drug to work. Historically, this has actually been an experimental procedure (tech stocks). Now, Alpha, Fold can forecast protein folding with 92. 4% precision. That's going to make it a lot easier to develop drugs that do what they're created to do. This was a development practically no one saw. However it's going to have extensive implications for curing illness. I forecast that Alpha, Fold will be 98% accurate by the end of 2021.
And, obviously, there will be plenty of financial investment chances in this area, too. Shifting topics It's going to be an excellent year for bitcoin. I'm bullish on it in 2021 (jeff brown top biotech stock 2021). That stated, I still believe bitcoin will continue to be unstable. We're close to all-time highs. I would not be amazed if it pulled back maybe substantially prior to going greater - melania trump. I've been covering bitcoin for a very long time now. One of the very first research study reports I ever published was on bitcoin. That remained in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $34,000 today.
But at the time of that initial recommendation, I entitled my report "What's the Big Deal With Bitcoin?" That shows you where the discussion was at the time. We were mostly informing readers. However that's not the big question anymore. Now we're seeing institutional money lastly take an interest in bitcoin. Massachusetts Mutual Life Insurance took a $100 million stake in bitcoin in December. This is not some small, specific niche business. Mass, Mutual is a relied on 170-year-old organization. So believe about that. In 5 years, we went from informing readers on what bitcoin is to a business like Mass, Mutual taking a $100 million stake.
And that's a huge factor I'm bullish on it this year. self-driving cars. Regards, Jeff Brown, Editor, The Bleeding Edge I have a reward forecast 2020 was a record year for IPOs. 552 U.S. companies went public the most in more than 20 years. These business raised a total of $172 billion. That's an all-time high beating the previous annual record by 43%. I anticipate 2021 will be another record year in IPOs. There are a lot of terrific personal business on the brink of striking the public markets And I have actually been dealing with a new way for you to invest even before these companies go public.
This chance has been building over the last few years. I can't wait to tell you all about it. Join me tomorrow at 8 p. m. ET for my Pre-IPO Code Occasion to find out all the details. Go right here to book your spot for complimentary.
Emma Walsh here, managing editor of the Journal. Regular Journal readers understand that tech isn't our usual beat (legacy report prediction). And when it pertains to tech investing, we leave it to the experts. Fortunately, we have a number of such specialists in our Rolodex. Our associate Jeff Brown will be familiar to our longtime readers. He is among the most accomplished tech investing professionals we understand (what is the legacy report predicting). In truth, he had a number of triple-digit returns in his Brownstone Research portfolios last year. Here's what Jeff believes the tech sector will bring us in 2021 Each year, I like to take a look at the big picture and predict what's simply around the corner.
That includes things like 5G networks, biotech, expert system, and far more. These patterns are experiencing rapid development and developing extraordinary chances for investors. I wish to make certain all our readers are prepared for what's next. And with that in mind, let me draw the picture of what I see can be found in the next 12 months Our new 5G (fifth-generation) wireless networks are a subject I have actually been covering for years now. korean actress. However despite what lots of readers might think, this is a pattern that's simply beginning. Even though the COVID-19 pandemic interrupted supply chains in 2015, an outstanding 250 million 5G-enabled gadgets were still sold.
And all of this eventually resulted in Apple delaying the release of the 5G-enabled i, Phone 12 by 2 months (jeff brown biotech picks). Losing two months of manufacturing and sales actually impacts how lots of 5G devices are offered in the calendar year. When you consider all of that, selling 250 million systems is impressive. More significantly, the delays triggered by the pandemic produced a lots of bottled-up need. Which need is now going to be pushed into 2021. In reality, I forecast that more than 500 million 5G devices will be shipped in 2021 - jeff brown 2021 predictions. And that's not my only 5G prediction When I've talked about 5G in the past, I've explained its three different phases.
In Stage Two, 5G gadgets go on sale. 5G phones and other items begin to reach consumers. And in Stage Three, 5G services start to be offered (jeff brown 2020 predictions). That's when we begin to see applications operating on 5G networks. Think about things like enormous multiplayer games over a cellphone. That's not possible with 4G. It will be with 5G. And my second 5G prediction for 2021 is that we will begin Stage Three by this summertime. This begins something of a virtuous cycle: The majority of individuals don't really appreciate the innovation. But they will care if there are amazing applications that can only be accessed with a 5G phone.
That leads to more 5G apps being established. In truth, 5G is going to open up a suite of extraordinary applications: self-driving cars and trucks, the Internet of Things, robotic surgical treatment, and more. All of these technologies require 5G. The financial investment opportunities going forward will be huge. Stepping far from 5G, the next important innovation I visualize in 2021 is CRISPR genetic editing. CRISPR stands for "clustered frequently interspaced brief palindromic repeat." It's a mouthful. But it's one of the most interesting advancements in biotechnology. At a high level, CRISPR is a technology that can edit our genetic makeup as if it were software application.
The program can crash or not function properly. CRISPR uses a similar concept however with our hereditary code. "Typos" in our genome can result in disease. CRISPR can correct these "typos." For several years, CRISPR was mainly a specific niche innovation that wasn't well understood. And throughout that time, there were really just three business operating in this area. However things are changing. CRISPR is no longer just theoretical. We're seeing real results. We're dealing with illness and seeing that this technology simply works. And as an outcome, a "2nd crop" of early-stage CRISPR companies is going public and providing unbelievable returns. This entire market is successfully a greenfield opportunity.
There's room for many business to exist in this area. jeff brown biotech genome sequencing. And there will be more. That's my prediction for CRISPR in 2021. I forecast that two or three more hereditary editing business will hold their IPOs. Sticking to biotechnology, we are seeing fantastic things occurring at the merging of biotech and expert system (AI). Google's AI subsidiary, Deep, Mind, just announced at the end of 2020 that its latest Alpha, Fold software application can properly forecast the folding of a protein based entirely on its amino acid series with 92. 4% precision. That is essential because the method a protein in the human body folds determines if a pharmaceutical will be able to bind to that protein and work.
Historically, this has been a trial-and-error procedure. Now, Alpha, Fold can forecast protein folding with 92. 4% precision. That's going to make it a lot easier to produce drugs that do what they're created to do. And here's my next forecast. I anticipate that Alpha, Fold will be 98% accurate by the end of 2021. And we will see not just one but numerous drug therapies produced utilizing this technology. This was among those breakthroughs that practically nobody saw. But it's going to have profound ramifications for curing disease. And, of course, there will be lots of financial investment chances in this area, too.
It's going to be a good year for bitcoin. I'm bullish on it in 2021. That said, I still think bitcoin will continue to be volatile. We're close to all-time highs. I would not be shocked if it drew back possibly substantially prior to going greater. I've been covering bitcoin for a long time now. Among the first research study reports I ever published was on bitcoin - jeff brown top biotech 2020. That remained in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $40,000 today. So that's a 16,500%+ return on financial investment for anybody who followed my suggestion. However at the time of that initial recommendation, I titled my report, "What's the Big Deal With Bitcoin?" That shows you where the discussion was at the time.
But nobody is asking that concern anymore. Now, we're seeing institutional cash lastly taking an interest in bitcoin. The big news was that Massachusetts Mutual Life Insurance took a $100 million stake in bitcoin in December. This is not some small, specific niche enterprise. social media. Mass, Mutual is a 150-year-old institution. So think about that. In five years, we went from informing readers on what bitcoin is to a company like Mass, Mutual taking a $100 million stake. The institutional adoption of bitcoin will continue. Which's a huge reason I'm bullish on it this year. Regards, Jeff Brown, Editor, The Bleeding Edge I have one more reward prediction In 2021, we're going to have another record year in IPOs. One site reports that Jeff Brown deserves about $27. 5 million and claims the details is up to date since February 2021, however we might not individually verify this claim. Given Jeff Brown's past, he likely has a substantial net worth, but we can't hammer down a precise figure at this moment. Brown is best known for his sage-like capability to choose winning innovation stocks. He spent more than 25 years investigating technology business like Qualcomm, NXP semiconductors, and Juniper Networks. Brown's extensive experience gives him an exceptional point of view on the marketplace. He's always on the hunt for new opportunities, and he shares many of his finest choices in the Near Future Report.
That's high praise, however it's not ridiculously reasoned. Brown has an outstanding credibility as a stock-picker, and he effectively anticipated a few of the biggest economic occasions of the previous 20 years. Although he doesn't appear to launch his choices to the public, the service's success is a direct indication of Brown's stock-picking expertise. Nobody on Wall Street gets it best whenever, however Jeff Brown's accurate predictions have made him legions of dedicated fans. That says a lot about his ability. The Future Report is released by Brownstone Research, a prominent monetary research publisher. Brownstone Research provides a number of research study services with a wide range of specializations - future report review.
The company is likewise connected with Bonner & Partners, another well-respected research study publisher - white house. On its website, Brownstone states its objective is to provide retail financiers with professional-grade research study: "For too long, the finest financial investment research has not been offered to individual financiers. It has been usually booked for financial investment banks, hedge funds, private equity, and high-net-worth clients. biotech stocks jeff brown. The mission of Brownstone Research is to make that type of exclusive research study offered to any investors looking to get an edge in the marketplaces. The goal is basic to deliver distinct and lucrative financial investment research found nowhere else." -Brownstone Research website excerpt from the Jeff Brown is the founder of Brownstone Research, and he likewise functions as the company's Chief Investment Analyst.
With Brown assisting the ship, Brownstone Research study is a powerhouse publisher with lots to offer its clients. After years of consistent success at the helm of top-tier business like Tesla and Area, X, Elon Musk is a home name throughout many of America. If you know even a bit about the marketplace, you understand that he has a credibility as a King Midas of sorts. tech stock. Everything he touches turns to gold! Jeff is aware of Elon Musk's executive prowess, so he always has an eye out for the Silicon Valley rock star's next relocation. This time, Jeff has an early lead on Elon's next huge project.
In fact, Brown believes S.A.V. self-driving cars. might be "the greatest pattern of the 2020s, and he's not alone. Take a look at these quotes from other well-known S.A.V. bulls: Elon's next big act will be marrying 2 cutting-edge innovations: synthetic intelligence and electrical cars. Musk hopes the mix will help him develop the very first fully-autonomous, self-driving cars ever. It's nothing except the automobile industry's Holy Grail. As you understand, electric vehicles and self-driving automobile stocks have been substantial this year, however the Wall Street machine has been big on buzz without much concrete result. Regardless of an extreme boost in competitors over the past couple of years, Brown still believes Musk has the very best chance of putting everything together.
tech might be the magic string that ties all of it together. S.A.V. represents Shared Autonomous Automobile, and it could be the future of transportation. Essentially, this technology would enable you to lease out your automobile as a self-governing, self-driving taxi when you're not utilizing it. You simply get out of the vehicle and press a button on an app that informs the automobile to "sign up with the fleet." Next thing you understand, you're relaxing on your sofa while your cars and truck shuttles ride-sharers around town. Best of all, you get to keep a significant piece of the revenues. It sounds crazy, but it could be closed than you think.